Steven Legrand Stone

US Patent:

62109499, Apr 3, 2001

Filed:

Nov 30, 1998

Appl. No.:

9/201139

Inventors:

Steven Stone - Midvale UT
Ping Jiang - Salt Lake City UT
Alexander Kamb - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C07H 2104
C12N 120
C12N 1585
C12N 1563

US Classification:

4352523

Abstract:

The present invention relates to the Multiple Tumor Suppressor (MTS) genes in mice, their expression products, and their homology to the human MTS genes. The human MTS genes are involved in human cancers. The invention is further related to the use of the MTS genes in the therapy, diagnosis and prognosis of human cancer. The invention further relates to mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

US Patent:

58437568, Dec 1, 1998

Filed:

Jul 28, 1995

Appl. No.:

8/508735

Inventors:

Steven Stone - Midvale UT
Ping Jiang - Salt Lake City UT
Alexander Kamb - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C07H 2104
C12N 1563
C12N 121

US Classification:

4352523

Abstract:

The present invention relates to the Multiple Tumor Suppressor (MTS) genes in mice, their expression products, and their homology to the human MTS genes. The human MTS genes are involved in human cancers. The invention is further related to the use of the MTS genes in the therapy, diagnosis and prognosis of human cancer. The invention further relates to mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.